Jefferies downgraded Regeneron Pharmaceuticals REGN from Buy to Hold and maintained a $179.00 price target.
Jefferies noted, "We conducted another wAMD survey which predicts limited near/mid-term upside to Eylea sales over our ests and current valuation which already reflect anticipated growth. Notably, benefit from potential cmpding driven decline in
Avastin use only modestly benefits Eylea. … Following REGN's Jan 8 pre- announcement of U.S. Eylea sales of $838M for Q4 2012 with FY2013 guidance of $1.2-$1.3B and based on our survey results, we increased our U.S. Eylea wAMD sales incrementally by 1-2% for 2013-17, modestly impacting the topline."
Regeneron Pharmaceuticals closed at $179.40 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in